Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What to do with targeted IL-2.

H N Lode1, R Xiang, P Perri

  • 1The Scripps Research Institute, Department of Immunology, La Jolla, California 92037, USA.

Drugs of Today (Barcelona, Spain : 1998)
|July 16, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Development and validation of a machine learning-based prognostic model for chronic rhinosinusitis with nasal polyps].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2026
Same author

Genetic and genomic analyses of the effect of heat stress, measured as temperature-humidity index, on cow fertility in Australian Holstein cattle.

Journal of dairy science·2026
Same author

[The overall study protocol for the West China Bone Health Cohort].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2025
Same author

A Comparative Study of the Clinical Efficacy of Superselective Adrenal Artery Embolization for Patients with Primary Aldosteronism.

American journal of hypertension·2025
Same author

[Unsupervised clustering analysis based on multidimensional features reveals distinct clinical characteristics and associated factors of different phenotypes in patients with chronic rhinosinusitis with nasal polyp].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2024
Same author

Archetypal clustering reveals physiological mechanisms linking milk yield and fertility in dairy cattle.

Journal of dairy science·2024
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Targeting interleukin-2 (IL-2) with immunocytokines eradicates tumors and enhances cancer vaccines. This approach shows promise for adjuvant cancer therapy, alone or combined with antiangiogenic strategies.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Cancer immunotherapy often aims to increase tumor immunogenicity.
  • Novel strategies involve delivering cytokines to the tumor microenvironment using antibody-cytokine fusion proteins (immunocytokines).

Purpose of the Study:

  • To summarize the therapeutic efficacy and immune mechanisms of targeting interleukin-2 (IL-2) to tumors.
  • To explore the use of IL-2 immunocytokines in combination with cancer vaccines and antiangiogenic therapies.

Main Methods:

  • Treatment of established melanoma, colon carcinoma, and neuroblastoma metastases in syngeneic mouse models with IL-2 immunocytokines.
  • Evaluation of therapeutic efficacy, immune responses (including NK and T-cell memory), and synergistic effects with antiangiogenic agents.

Related Experiment Videos

Main Results:

  • IL-2 immunocytokines eradicated established metastases and induced a protective vaccination effect against subsequent tumor challenges.
  • Targeted IL-2 mediated antitumor responses via NK cells in neuroblastoma models and amplified memory responses from cancer vaccines.
  • Combination therapy with an antiangiogenic inhibitor of integrin alpha(v)beta(3) demonstrated synergistic antitumor effects in multiple models.

Conclusions:

  • Targeted IL-2 immunocytotherapy is a potent strategy for eradicating established tumors and generating long-term immunity.
  • IL-2 immunocytokines can enhance existing cancer vaccines and synergize with antiangiogenic treatments.
  • Targeted IL-2 holds significant potential as an adjuvant cancer therapy, used alone or in combination regimens.